Loading stock data…
Exagen Inc. (XGN)
$7.30-0.28 (-3.69%)
Market ClosedLast close Sep 8
Exagen Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Exagen Inc. in the Healthcare sector is trading at $7.30 with a market capitalization of $110M. Wall Street consensus targets $9.86 (7 analysts), implying a +35.0% move over the next 12 months. The stock is currently 40% below its 52-week high of $12.23, remaining 53.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +35.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $17.31M↑ | $16.63M↓ | $17.24M↑ | $17.20M↑ | $15.50M |
| Gross Profit | $10.21M↑ | $9.21M↓ | $10.07M↓ | $10.39M↑ | $9.12M |
| Operating Income | -$3.41M↑ | -$4.97M↓ | -$3.10M↓ | -$2.63M↑ | -$3.37M |
| Net Income | -$3.97M↑ | -$4.67M↑ | -$7.09M↓ | -$4.44M↓ | -$3.75M |
Peer Comparison
JNJUNHPFE
Fundamentals
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$109.69M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.81
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-139.73%
Volume
Today's trading volume
151,901
Recent News
Exagen (XGN) Q2 2026 Earnings Call Transcript
Record revenue and near break-even adjusted EBITDA signal progress toward profitability.
Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution
Exagen now carries a modestly higher implied fair value, with the target shifting from about US$8.67 to roughly US$9.71 per share. Analysts link this change to a mix of optimism around the AVISE CTD autoimmune testing portfolio and caution around execution and valuation, as they assess how the current business can support the updated target. Read on to see what this may mean for you as an investor and how to track the evolving Exagen narrative from here. Analyst Price Targets don't always...
Exagen Inc. Q2 2026 Earnings Call Summary
Moby summary of Exagen Inc.'s Q2 2026 earnings call
Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability
Exagen Inc (XGN) reports record Q2 revenue of $19.9 million, nearly achieving adjusted EBITDA breakeven, and raises full-year guidance.
Exagen Q2 Earnings Call Highlights
Exagen (NASDAQ:XGN) reported record second-quarter revenue as growth in AVISE CTD test volume, average selling price and Pharma Services revenue brought the autoimmune diagnostics company close to adjusted EBITDA break-even. Revenue for the quarter ended June 30 rose 16% year over year and 15% sequ